|
US4186745A
(en)
|
1976-07-30 |
1980-02-05 |
Kauzlarich James J |
Porous catheters
|
|
US4500707A
(en)
|
1980-02-29 |
1985-02-19 |
University Patents, Inc. |
Nucleosides useful in the preparation of polynucleotides
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US5132418A
(en)
|
1980-02-29 |
1992-07-21 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4668777A
(en)
|
1981-03-27 |
1987-05-26 |
University Patents, Inc. |
Phosphoramidite nucleoside compounds
|
|
US4973679A
(en)
|
1981-03-27 |
1990-11-27 |
University Patents, Inc. |
Process for oligonucleo tide synthesis using phosphormidite intermediates
|
|
US4373071A
(en)
|
1981-04-30 |
1983-02-08 |
City Of Hope Research Institute |
Solid-phase synthesis of polynucleotides
|
|
SE8205892D0
(sv)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5036006A
(en)
|
1984-11-13 |
1991-07-30 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
DE3687030T2
(de)
|
1985-03-15 |
1993-03-11 |
Eugene Stirchak |
Stereoregulare polynukleotiden bindende polymere.
|
|
US5153319A
(en)
|
1986-03-31 |
1992-10-06 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4853228A
(en)
|
1987-07-28 |
1989-08-01 |
Micro-Pak, Inc. |
Method of manufacturing unilamellar lipid vesicles
|
|
JPH0731857B2
(ja)
|
1988-02-19 |
1995-04-10 |
三洋電機株式会社 |
磁気記録再生装置におけるリール台駆動装置
|
|
AU631377B2
(en)
|
1988-08-25 |
1992-11-26 |
Liposome Company, Inc., The |
Affinity associated vaccine
|
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
|
US5047524A
(en)
|
1988-12-21 |
1991-09-10 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5262530A
(en)
|
1988-12-21 |
1993-11-16 |
Applied Biosystems, Inc. |
Automated system for polynucleotide synthesis and purification
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US6867195B1
(en)
|
1989-03-21 |
2005-03-15 |
Vical Incorporated |
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
|
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
|
FR2645020B1
(fr)
|
1989-03-28 |
1994-06-10 |
Vila Jorge |
Medicament pour le traitement des maladies infectieuses dues aux retrovirus ainsi que pour le traitement des tumeurs
|
|
HU212924B
(en)
|
1989-05-25 |
1996-12-30 |
Chiron Corp |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5674192A
(en)
|
1990-12-28 |
1997-10-07 |
Boston Scientific Corporation |
Drug delivery
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
FR2676072B1
(fr)
|
1991-05-03 |
1994-11-18 |
Transgene Sa |
Vecteur de delivrance d'arn.
|
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
NZ245015A
(en)
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
|
US6054288A
(en)
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
|
US5693535A
(en)
|
1992-05-14 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
HIV targeted ribozymes
|
|
US5750390A
(en)
|
1992-08-26 |
1998-05-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
|
|
US5340740A
(en)
|
1992-05-15 |
1994-08-23 |
North Carolina State University |
Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
|
|
AU4528493A
(en)
|
1992-06-04 |
1994-01-04 |
Regents Of The University Of California, The |
In vivo gene therapy with intron-free sequence of interest
|
|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
|
US20020102273A1
(en)
|
1995-08-08 |
2002-08-01 |
Robert B. Grieve |
Use of alphavirus expression vectors to produce parasite anitgens
|
|
ES2162139T5
(es)
|
1993-03-23 |
2008-05-16 |
Smithkline Beecham Biologicals S.A. |
Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
|
|
EP0702516A4
(en)
|
1993-06-01 |
1998-04-22 |
Life Technologies Inc |
GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
|
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
|
CA2167042A1
(en)
|
1993-07-15 |
1995-01-26 |
Kyle J. Lindstrom |
Imidazo[4,5-c]pyridin-4-amines
|
|
US6015686A
(en)
*
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
US5397307A
(en)
|
1993-12-07 |
1995-03-14 |
Schneider (Usa) Inc. |
Drug delivery PTCA catheter and method for drug delivery
|
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
|
JP3403233B2
(ja)
|
1994-01-20 |
2003-05-06 |
テルモ株式会社 |
バルーンカテーテル
|
|
WO1995027721A1
(en)
|
1994-04-07 |
1995-10-19 |
Akzo Nobel N.V. |
Freeze-dried compositions comprising rna
|
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US5993850A
(en)
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
FR2726003B1
(fr)
|
1994-10-21 |
2002-10-18 |
Agronomique Inst Nat Rech |
Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
|
|
US6083741A
(en)
|
1994-11-17 |
2000-07-04 |
Imperial College Of Science Technology And Medicine |
Internalisation of DNA, using conjugates of poly-l-lysine and an integrin receptor ligand
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6071890A
(en)
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
|
US5965434A
(en)
|
1994-12-29 |
1999-10-12 |
Wolff; Jon A. |
Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
|
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
|
US5700642A
(en)
|
1995-05-22 |
1997-12-23 |
Sri International |
Oligonucleotide sizing using immobilized cleavable primers
|
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
CA2230033C
(en)
|
1995-09-27 |
2010-01-26 |
Peter L. Collins |
Production of infectious respiratory syncytial virus from cloned nucleotide sequences
|
|
JP2000505802A
(ja)
*
|
1996-02-12 |
2000-05-16 |
コブラ セラピューティクス リミテッド |
ワクチン接種の新規な方法、ならびにそのための、第１のエピトープをコードする核酸および第２のエピトープを含有するペプチドを含むワクチン
|
|
DE19605548A1
(de)
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
|
US6451592B1
(en)
|
1996-04-05 |
2002-09-17 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
JP2001503735A
(ja)
|
1996-07-03 |
2001-03-21 |
ユニバーシティ オブ ピッツバーグ |
親水性活性試薬のためのエマルジョン処方物
|
|
WO1998001148A1
(en)
|
1996-07-09 |
1998-01-15 |
President And Fellows Of Harvard College |
Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein
|
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
|
ES2305157T3
(es)
|
1996-09-13 |
2008-11-01 |
Lipoxen Technologies Limited |
Liposomas.
|
|
US6395302B1
(en)
|
1996-11-19 |
2002-05-28 |
Octoplus B.V. |
Method for the preparation of microspheres which contain colloidal systems
|
|
EP1005368B1
(en)
|
1997-03-10 |
2009-09-02 |
Ottawa Hospital Research Institute |
Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
|
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
|
DE69841002D1
(de)
|
1997-05-14 |
2009-09-03 |
Univ British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
|
US6048546A
(en)
|
1997-07-31 |
2000-04-11 |
Sandia Corporation |
Immobilized lipid-bilayer materials
|
|
US6060308A
(en)
|
1997-09-04 |
2000-05-09 |
Connaught Laboratories Limited |
RNA respiratory syncytial virus vaccines
|
|
US6090619A
(en)
|
1997-09-08 |
2000-07-18 |
University Of Florida |
Materials and methods for intracellular delivery of biologically active molecules
|
|
WO1999016500A2
(en)
|
1997-10-01 |
1999-04-08 |
Medtronic Ave, Inc. |
Drug delivery and gene therapy delivery system
|
|
GB9725084D0
(en)
|
1997-11-28 |
1998-01-28 |
Medeva Europ Ltd |
Vaccine compositions
|
|
US6009406A
(en)
|
1997-12-05 |
1999-12-28 |
Square D Company |
Methodology and computer-based tools for re-engineering a custom-engineered product line
|
|
GB9726555D0
(en)
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Vaccine
|
|
WO1999052549A1
(en)
|
1998-04-09 |
1999-10-21 |
Smithkline Beecham Biologicals S.A. |
Adjuvant compositions
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
|
WO2000000616A2
(en)
|
1998-06-29 |
2000-01-06 |
U.S. Medical Research Institute Of Infectious Diseases |
Marburg virus vaccines
|
|
EP1096921B1
(en)
|
1998-07-20 |
2003-04-16 |
Protiva Biotherapeutics Inc. |
Liposomal encapsulated nucleic acid-complexes
|
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
|
CZ301212B6
(cs)
|
1998-10-16 |
2009-12-09 |
Smithkline Beecham Biologicals S. A. |
Vakcinacní prostredek
|
|
EP1980617A1
(en)
|
1998-12-31 |
2008-10-15 |
Novartis Vaccines and Diagnostics, Inc. |
Improved expression of HIV polypeptides and production of virus-like particles
|
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
|
JP2003509473A
(ja)
|
1999-09-24 |
2003-03-11 |
スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム |
ワクチン
|
|
KR20020048942A
(ko)
|
1999-09-24 |
2002-06-24 |
장 스테판느 |
폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
|
|
EP1222289B1
(en)
|
1999-10-20 |
2008-04-16 |
The Johns Hopkins University School Of Medicine |
Chimeric immunogenic compositions and nucleic acids encoding them
|
|
US8541008B2
(en)
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
|
AU3108001A
(en)
|
2000-01-20 |
2001-12-24 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
|
US20030212022A1
(en)
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
|
WO2001079253A1
(en)
|
2000-04-18 |
2001-10-25 |
Human Genome Sciences, Inc. |
Extracellular matrix polynucleotides, polypeptides, and antibodies
|
|
CN1254234C
(zh)
|
2000-06-09 |
2006-05-03 |
莱古伦公司 |
质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
|
|
ATE440861T1
(de)
|
2000-07-03 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
Immunisierung gegen chlamydia pneumoniae
|
|
US7318928B2
(en)
|
2000-08-01 |
2008-01-15 |
The Johns Hopkins University |
Molecular vaccine linking intercellular spreading protein to an antigen
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
AU9475001A
(en)
|
2000-09-26 |
2002-04-08 |
Hybridon Inc |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
|
ATE320792T1
(de)
|
2000-09-28 |
2006-04-15 |
Chiron Corp |
Mikropartikel zur verabreichung von heterologen nukleinsäure
|
|
WO2002034771A2
(en)
|
2000-10-27 |
2002-05-02 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
|
US7731975B2
(en)
|
2001-01-31 |
2010-06-08 |
The United States Of America As Represented By The Secretary Of The Army |
Chimeric filovirus glycoprotein
|
|
EP1363660A4
(en)
|
2001-02-01 |
2006-06-21 |
Univ Johns Hopkins |
HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
|
|
US20030040498A1
(en)
|
2001-03-14 |
2003-02-27 |
Ansardi David Calvert |
Oncolytic RNA replicons
|
|
AU2002256398A2
(en)
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US20030077251A1
(en)
|
2001-05-23 |
2003-04-24 |
Nicolas Escriou |
Replicons derived from positive strand RNA virus genomes useful for the production of heterologous proteins
|
|
DE50214201D1
(de)
|
2001-06-05 |
2010-03-25 |
Curevac Gmbh |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
|
|
EP1423142A1
(en)
|
2001-08-31 |
2004-06-02 |
Chiron SRL. |
Helicobacter pylori vaccination with a combination of caga, vaca and nap proteins
|
|
DE60233061D1
(de)
|
2001-09-06 |
2009-09-03 |
Alphavax Inc |
Alphavirus replikon-vektorsysteme
|
|
EP1425040A2
(en)
|
2001-09-14 |
2004-06-09 |
Cytos Biotechnology AG |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
|
ATE447967T1
(de)
|
2001-09-14 |
2009-11-15 |
Cytos Biotechnology Ag |
Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
|
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
FR2832423B1
(fr)
|
2001-11-22 |
2004-10-08 |
Vivalis |
Systeme d'expression de proteines exogenes dans un systeme aviaire
|
|
US20050163832A1
(en)
|
2002-02-13 |
2005-07-28 |
Vladimir Torchilin |
Intracellular delivery of therapeutic agents
|
|
DE10207177A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Fakultativ kationische Lipide
|
|
FR2836924B1
(fr)
|
2002-03-08 |
2005-01-14 |
Vivalis |
Lignees de cellules aviaires utiles pour la production de substances d'interet
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
US7604803B2
(en)
|
2002-07-05 |
2009-10-20 |
Lipoxen Technologies Limited |
Method to enhance an immune response of nucleic acid vaccination
|
|
AU2003266301A1
(en)
|
2002-08-22 |
2004-03-11 |
Cytos Biotechnology Ag |
Inducible alphaviral/orip based gene expression system
|
|
AU2003267785C1
(en)
|
2002-09-13 |
2009-12-24 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
AU2003297039B2
(en)
*
|
2002-12-13 |
2009-03-05 |
Alphavax, Inc. |
Multi-antigenic alphavirus replicon particles and methods
|
|
DK2311848T3
(da)
|
2002-12-23 |
2013-10-14 |
Vical Inc |
Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
|
|
EP1587473A4
(en)
|
2002-12-27 |
2008-08-13 |
Novartis Vaccines & Diagnostic |
THIOSEMICARBAZONE AS VIRUZIDES AND IMMUNOSTIMULATORS
|
|
ES2391770T3
(es)
|
2003-01-21 |
2012-11-29 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos de triptantrina para la potenciación inmune
|
|
WO2004069148A2
(en)
|
2003-02-04 |
2004-08-19 |
Bar-Ilan University |
Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
|
|
WO2004076645A2
(en)
|
2003-02-27 |
2004-09-10 |
University Of Massachusetts |
Compositions and methods for cytomegalovirus treatment
|
|
KR101518309B1
(ko)
*
|
2003-03-20 |
2015-05-08 |
알파벡스, 인크. |
개선된 알파바이러스 레플리콘 및 헬퍼 구축물
|
|
DE10319208B4
(de)
|
2003-04-29 |
2005-10-20 |
Grenzebach Bsh Gmbh |
Furniermessermaschine
|
|
CA2527301A1
(en)
|
2003-05-30 |
2004-12-09 |
Nippon Shinyaku Co., Ltd. |
Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
|
|
JP4896715B2
(ja)
|
2003-06-26 |
2012-03-14 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物
|
|
EP1651666B1
(en)
|
2003-07-11 |
2009-05-27 |
Alphavax, Inc. |
Alphavirus-based cytomegalovirus vaccines
|
|
US7368537B2
(en)
|
2003-07-15 |
2008-05-06 |
Id Biomedical Corporation Of Quebec |
Subunit vaccine against respiratory syncytial virus infection
|
|
SG190613A1
(en)
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
|
EP1648500B1
(en)
|
2003-07-31 |
2014-07-09 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for streptococcus pyogenes
|
|
EP1512393A1
(de)
|
2003-09-08 |
2005-03-09 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
|
|
EP1528101A1
(en)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalized avian cell lines for virus production
|
|
EP1687033A4
(en)
|
2003-11-12 |
2008-06-11 |
Us Navy |
IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE
|
|
US7303881B2
(en)
|
2004-04-30 |
2007-12-04 |
Pds Biotechnology Corporation |
Antigen delivery compositions and methods of use
|
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
|
AU2005248361B2
(en)
|
2004-05-18 |
2010-03-11 |
Vical Incorporated |
Influenza virus vaccine composition and methods of use
|
|
US20050266550A1
(en)
|
2004-05-18 |
2005-12-01 |
Alphavax, Inc. |
TC-83-derived alphavirus vectors, particles and methods
|
|
EP2848692B1
(en)
|
2004-05-21 |
2017-08-16 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
|
GB0411428D0
(en)
|
2004-05-21 |
2004-06-23 |
Got A Gene Ab |
Vectors
|
|
AU2005252273B2
(en)
|
2004-06-07 |
2011-04-28 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
JP4764426B2
(ja)
|
2004-06-07 |
2011-09-07 |
プロチバ バイオセラピューティクス インコーポレイティッド |
カチオン性脂質および使用方法
|
|
WO2006085983A2
(en)
*
|
2004-07-09 |
2006-08-17 |
University Of North Carolina At Chapel Hill |
Viral adjuvants
|
|
US20060051405A1
(en)
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
|
ATE465173T1
(de)
|
2004-09-24 |
2010-05-15 |
Intercell Ag |
Verändertes vp-1capsidprotein von parvovirus b19
|
|
JP5086082B2
(ja)
|
2004-10-01 |
2012-11-28 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Ｃ型肝炎ウイルス複製系
|
|
JP2008520600A
(ja)
|
2004-11-19 |
2008-06-19 |
ノヴォソム アクチェンゲゼルシャフト |
局所投与のための医薬組成物におけるまたはそれに関する改善
|
|
GB2421025A
(en)
|
2004-12-09 |
2006-06-14 |
Oxxon Therapeutics Ltd |
HSV vaccination vectors
|
|
WO2007086883A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
US8062644B2
(en)
|
2005-02-18 |
2011-11-22 |
Novartis Vaccines & Diagnostics Srl. |
Immunogens from uropathogenic Escherichia coli
|
|
ES2595363T3
(es)
|
2005-02-18 |
2016-12-29 |
J. Craig Venter Institute, Inc. |
Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
|
|
JP2008531672A
(ja)
|
2005-03-02 |
2008-08-14 |
イギリス国 |
医薬組成物
|
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
BRPI0609460A2
(pt)
|
2005-03-30 |
2010-04-13 |
Novartis Vaccines & Diagnostics Inc |
haemophilus influenzae tipo b
|
|
US7618393B2
(en)
|
2005-05-03 |
2009-11-17 |
Pharmajet, Inc. |
Needle-less injector and method of fluid delivery
|
|
EP1891096A2
(en)
|
2005-05-12 |
2008-02-27 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for chlamydia trachomatis
|
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
|
WO2007014754A1
(en)
|
2005-08-02 |
2007-02-08 |
I.D.M. Immuno-Designed Molecules |
Process for the preparation of liposomal formulations
|
|
US7951384B2
(en)
|
2005-08-05 |
2011-05-31 |
University Of Massachusetts |
Virus-like particles as vaccines for paramyxovirus
|
|
HUE043492T2
(hu)
|
2005-08-23 |
2019-08-28 |
Univ Pennsylvania |
Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
|
|
WO2007107304A2
(en)
|
2006-03-17 |
2007-09-27 |
Novosom Ag |
An efficient method for loading amphoteric liposomes with nucleic acid active substances
|
|
EP1764089A1
(en)
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
CA2624450C
(en)
|
2005-09-29 |
2014-02-04 |
Elan Pharmaceuticals, Inc. |
Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
|
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
|
JP2007112768A
(ja)
|
2005-10-24 |
2007-05-10 |
Kyoto Univ |
肝指向性リポソーム組成物
|
|
EP1954306A2
(en)
|
2005-10-25 |
2008-08-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Compositions comprising yersinia pestis antigens
|
|
WO2007081447A2
(en)
|
2005-11-22 |
2007-07-19 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
|
CA2631714C
(en)
|
2005-12-02 |
2014-09-16 |
Novartis Ag |
Nanoparticles for use in immunogenic compositions
|
|
CA2654563A1
(en)
*
|
2006-06-07 |
2007-12-21 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
EP2035581B1
(en)
|
2006-06-21 |
2012-09-26 |
The Scripps Research Institute |
Dna composition against tumor stromal antigen fap and methods of use thereof
|
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
|
PT3207941T
(pt)
|
2006-09-07 |
2020-04-02 |
Scott & White Memorial Hospital |
Métodos e composições baseados em conjugados de toxina diftérica-interleucina-3
|
|
WO2008033966A2
(en)
|
2006-09-12 |
2008-03-20 |
Alphavax, Inc. |
Alphavirus replicon particles matched to protein antigens as immunological adjuvants
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US20100015218A1
(en)
|
2007-02-16 |
2010-01-21 |
Vasant Jadhav |
Compositions and methods for potentiated activity of biologically active molecules
|
|
WO2008109806A2
(en)
|
2007-03-08 |
2008-09-12 |
Massachusetts Institute Of Technology |
Electrostatic coating of particles for drug delivery
|
|
US8877206B2
(en)
|
2007-03-22 |
2014-11-04 |
Pds Biotechnology Corporation |
Stimulation of an immune response by cationic lipids
|
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
|
US8748591B2
(en)
|
2007-04-17 |
2014-06-10 |
The Board Of Regents Of The University Of Texas System |
Chimeric sindbis-western equine encephalitis virus and uses thereof
|
|
JP5475643B2
(ja)
|
2007-05-04 |
2014-04-16 |
マリーナ バイオテック，インコーポレイテッド |
アミノ酸脂質およびその使用
|
|
JP2010528591A
(ja)
|
2007-05-23 |
2010-08-26 |
マンカインド コーポレイション |
マルチシストロン性ベクター及びそれらの設計方法
|
|
DE102007029471A1
(de)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
Neue fakultativ kationische Sterole
|
|
US7850977B2
(en)
|
2007-06-21 |
2010-12-14 |
Alphavax, Inc. |
Promoterless cassettes for expression of alphavirus structural proteins
|
|
US8202518B2
(en)
|
2007-07-04 |
2012-06-19 |
Ribovax Biotechnologies S.A. |
Antibodies against human cytomegalovirus (HCMV)
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
US20110177155A1
(en)
|
2007-08-21 |
2011-07-21 |
Immune Disease Institute, Inc. |
Methods of delivery of agents to leukocytes and endothelial cells
|
|
GB0717187D0
(en)
|
2007-09-04 |
2007-10-17 |
Novartis Ag |
Compositions comprising yersinia pestis antigens
|
|
WO2009042794A2
(en)
|
2007-09-26 |
2009-04-02 |
Vanderbilt University |
Venezuelan equine encephalitis replicons expressing paramyxovirus glycoproteins as vaccine
|
|
EP2042193A1
(en)
|
2007-09-28 |
2009-04-01 |
Biomay AG |
RNA Vaccines
|
|
US20090091591A1
(en)
|
2007-10-07 |
2009-04-09 |
Yohanan Sivan |
Printing Systems And Methods For Generating Relief Images
|
|
CA2705787A1
(en)
|
2007-11-26 |
2009-06-25 |
Novartis Ag |
Methods of generating alphavirus particles
|
|
EP2067749A1
(en)
|
2007-11-29 |
2009-06-10 |
Total Petrochemicals France |
Process for purification of an aqueous phase containing polyaromatics
|
|
WO2009074861A2
(en)
|
2007-12-10 |
2009-06-18 |
Powderject Research Limited |
Improved vaccine
|
|
WO2009111088A2
(en)
|
2008-01-02 |
2009-09-11 |
The Johns Hopkins University |
Antitumor immunization by liposomal delivery of vaccine to the spleen
|
|
US20110117125A1
(en)
|
2008-01-02 |
2011-05-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for the delivery of nucleic acids
|
|
ITMI20081249A1
(it)
|
2008-07-09 |
2010-01-09 |
Novartis Vaccines & Diagnostic |
Immunogeni di escherichia coli con solubilità migliorata.
|
|
PL2268618T3
(pl)
|
2008-03-03 |
2015-11-30 |
Novartis Ag |
Związki i kompozycje jako modulatory aktywności receptorów TLR
|
|
WO2009109860A2
(en)
|
2008-03-06 |
2009-09-11 |
Novartis Ag |
Mutant forms of chlamydia htra
|
|
US8058069B2
(en)
|
2008-04-15 |
2011-11-15 |
Protiva Biotherapeutics, Inc. |
Lipid formulations for nucleic acid delivery
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
|
WO2009132206A1
(en)
|
2008-04-25 |
2009-10-29 |
Liquidia Technologies, Inc. |
Compositions and methods for intracellular delivery and release of cargo
|
|
US20100040650A1
(en)
|
2008-05-30 |
2010-02-18 |
Crowe Jr James E |
Virus-Like paramyxovirus particles and vaccines
|
|
EP2130912A1
(en)
|
2008-06-04 |
2009-12-09 |
Institut für Viruskrankeiten und Immunprophylaxe |
Pestivirus replicons providing an RNA-based viral vector system
|
|
WO2009156852A1
(en)
|
2008-06-25 |
2009-12-30 |
Novartis Ag |
Rapid responses to delayed booster immunisations
|
|
EP2310494A1
(en)
|
2008-06-25 |
2011-04-20 |
ProBioGen AG |
Cell line for propagation of highly attenuated alphaviruses
|
|
JP5475774B2
(ja)
|
2008-07-16 |
2014-04-16 |
インスティテュート フォー リサーチ イン バイオメディシン |
ヒトサイトメガロウイルス中和抗体およびその使用
|
|
EP2352759B1
(en)
|
2008-07-16 |
2017-11-01 |
Institute for Research in Biomedicine |
Human cytomegalovirus neutralizing antibodies and use thereof
|
|
JP2010025644A
(ja)
|
2008-07-16 |
2010-02-04 |
Kochi Univ Of Technology |
硝酸イオンの呈色試薬並びにこれを用いた硝酸イオンの検出及び定量方法
|
|
US20110280949A1
(en)
*
|
2008-08-06 |
2011-11-17 |
Padma Malyala |
Microparticles for use in immunogenic compositions
|
|
CL2008002322A1
(es)
|
2008-08-07 |
2009-06-05 |
Univ Concepcion |
Formulacion farmaceutica veterinaria que comprende un sistema vectorial viral constituido por una particula recombinante de arn que codifica una cu/zn superoxido dismutasa de la bacteria patogena de bovinos brucella abortus, y al menos un alfavirus arn perteneciente a la familia del virus semliki forest (sfv), util como vacuna.
|
|
WO2010019718A2
(en)
|
2008-08-13 |
2010-02-18 |
California Institute Of Technology |
Carrier nanoparticles and related compositions, methods and systems
|
|
US20110177122A1
(en)
|
2008-09-26 |
2011-07-21 |
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services |
Dna prime/activated vaccine boost immunization to influenza virus
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
MX353900B
(es)
|
2008-11-07 |
2018-02-01 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
|
CN105152939A
(zh)
|
2008-11-10 |
2015-12-16 |
阿尔尼拉姆医药品有限公司 |
用于递送治疗剂的脂质和组合物
|
|
AU2009316680B2
(en)
|
2008-11-18 |
2016-03-24 |
Takeda Vaccines, Inc. |
RSV F VLPs and methods of manufacture and use thereof
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
CA2758490C
(en)
|
2009-04-14 |
2023-05-02 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
|
KR20230098713A
(ko)
|
2009-06-10 |
2023-07-04 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
JP4900536B2
(ja)
|
2009-07-02 |
2012-03-21 |
コニカミノルタホールディングス株式会社 |
特定の分散剤を含有する外水相を利用する二段階乳化法による単胞リポソームの製造方法、ならびに当該単胞リポソームの製造方法を用いる単胞リポソーム分散液またはその乾燥粉末の製造方法
|
|
US20110300205A1
(en)
*
|
2009-07-06 |
2011-12-08 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
SI3178490T1
(sl)
|
2009-07-15 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Sestavki proteina F RSV-ja in postopki za pripravo le-teh
|
|
US8277919B2
(en)
|
2009-07-23 |
2012-10-02 |
VMO Systems, Inc. |
Reflective coating for an optical disc
|
|
DK2459231T3
(en)
|
2009-07-31 |
2016-09-05 |
Ethris Gmbh |
RNA with a combination of unmodified and modified nucleotides for protein expression
|
|
ES2443952T3
(es)
*
|
2009-09-02 |
2014-02-21 |
Novartis Ag |
Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
|
|
JO3257B1
(ar)
*
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
US20110070260A1
(en)
|
2009-09-09 |
2011-03-24 |
Baric Ralph S |
Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
|
|
JP5823405B2
(ja)
|
2009-11-04 |
2015-11-25 |
ザ ユニバーシティ オブ ブリティッシュ コロンビア |
核酸含有脂質粒子および関連方法
|
|
EP3403647A1
(en)
|
2009-12-01 |
2018-11-21 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
EP3287525B1
(en)
|
2009-12-07 |
2019-10-23 |
The Trustees of The University of Pennsylvania |
Rna preparations comprising purified modified rna for reprogramming cells
|
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
Martin A. Maier |
Lipid particles for delivery of nucleic acids
|
|
EP3721943A1
(en)
|
2009-12-23 |
2020-10-14 |
Novartis AG |
Lipids, lipid compositions and methods of using them
|
|
US20130101609A1
(en)
*
|
2010-01-24 |
2013-04-25 |
Novartis Ag |
Irradiated biodegradable polymer microparticles
|
|
EP2544693B1
(en)
|
2010-03-09 |
2017-09-13 |
Biomedical Research Models, Inc. |
A novel mucosal vaccination approach for herpes simplex virus type-2
|
|
US9744228B2
(en)
*
|
2010-04-07 |
2017-08-29 |
Norvartis Ag |
Method for generating a parvovirus B19 virus-like particle
|
|
EP3153578A1
(en)
*
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
|
BR112013000244A2
(pt)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipossomas com lipídeos apresentando pka vantajoso para administração de rna
|
|
US9770463B2
(en)
|
2010-07-06 |
2017-09-26 |
Glaxosmithkline Biologicals Sa |
Delivery of RNA to different cell types
|
|
ES2649896T3
(es)
|
2010-07-06 |
2018-01-16 |
Glaxosmithkline Biologicals Sa |
Emulsiones catiónicas de aceite en agua
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
US9192661B2
(en)
*
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
PL2590676T3
(pl)
|
2010-07-06 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna
|
|
US8898852B2
(en)
|
2010-08-04 |
2014-12-02 |
Honeywell International Inc. |
Air burst to clear detection window
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
JP5908477B2
(ja)
|
2010-08-31 |
2016-04-26 |
ノバルティス アーゲー |
タンパク質をコードするｒｎａのリポソームによる送達に適した脂質
|
|
MX341989B
(es)
|
2010-08-31 |
2016-09-09 |
Novartis Ag * |
Liposomas pequeños para el suministro de arn que codifica el inmunogeno.
|
|
RS63315B1
(sr)
*
|
2010-08-31 |
2022-07-29 |
Glaxosmithkline Biologicals Sa |
Pegilovani lipozomi za isporuku rnk koja kodira imunogen
|
|
WO2012034025A2
(en)
|
2010-09-09 |
2012-03-15 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
|
EP3431485B2
(en)
|
2010-10-01 |
2024-09-04 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
CA2814386C
(en)
*
|
2010-10-11 |
2019-08-20 |
Novartis Ag |
Antigen delivery platforms
|
|
WO2012061098A1
(en)
|
2010-10-25 |
2012-05-10 |
Stepan Company |
Quaternized fatty amines, amidoamines, and their derivatives from natural oil metathesis
|
|
WO2012092569A2
(en)
|
2010-12-31 |
2012-07-05 |
Selecta Biosciences, Inc. |
Compositions comprising immunostimulatory nucleic acids and related methods
|
|
HRP20190791T1
(hr)
*
|
2011-01-26 |
2019-06-28 |
Glaxosmithkline Biologicals Sa |
Režim imuniziranja protiv rsv
|
|
WO2012106377A2
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2012135805A2
(en)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Delivery and formulation of engineered nucleic acids
|
|
SI3275892T1
(sl)
*
|
2011-05-13 |
2020-06-30 |
Glaxosmithkline Biologicals S.A. |
Prefuzijski RSV F antigeni
|
|
EP2710136A4
(en)
|
2011-05-17 |
2015-01-21 |
Moderna Therapeutics Inc |
MANIPULATED NUCLEIC ACIDS AND USE METHOD FOR NON-HUMAN SPINE
|
|
CA3198966A1
(en)
|
2011-06-08 |
2012-12-13 |
Translate Bio, Inc. |
Cleavable lipids
|
|
US20140206753A1
(en)
|
2011-06-08 |
2014-07-24 |
Shire Human Genetic Therapies, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
US9655845B2
(en)
*
|
2011-07-06 |
2017-05-23 |
Glaxosmithkline Biologicals, S.A. |
Oil-in-water emulsions that contain nucleic acids
|
|
EP4115875A1
(en)
|
2011-07-06 |
2023-01-11 |
GlaxoSmithKline Biologicals S.A. |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
CA2840989A1
(en)
*
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
EP2729168A2
(en)
*
|
2011-07-06 |
2014-05-14 |
Novartis AG |
Immunogenic compositions and uses thereof
|
|
MX350258B
(es)
|
2011-07-06 |
2017-08-31 |
Novartis Ag |
Emulsiones cationicas de aceite en agua.
|
|
SG10201602456WA
(en)
|
2011-08-31 |
2016-04-28 |
Novartis Ag |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
WO2013039861A2
(en)
|
2011-09-12 |
2013-03-21 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
CN104105504A
(zh)
*
|
2011-10-11 |
2014-10-15 |
诺华股份有限公司 |
重组多顺反子核酸分子
|
|
EP2766385A2
(en)
*
|
2011-10-12 |
2014-08-20 |
Novartis AG |
Cmv antigens and uses thereof
|
|
EP2791364A4
(en)
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
PROCESS FOR RESPONSE TO A BIOLOGICAL THREAT
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
JP2015510495A
(ja)
|
2011-12-21 |
2015-04-09 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
器官または器官移植片の生存可能性または寿命を延長する方法
|
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
DE18200782T1
(de)
|
2012-04-02 |
2021-10-21 |
Modernatx, Inc. |
Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
|
|
CA2892529C
(en)
|
2012-11-26 |
2023-04-25 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
AU2014204826A1
(en)
*
|
2013-01-10 |
2015-07-09 |
Seqirus UK Limited |
Influenza virus immunogenic compositions and uses thereof
|
|
US9504747B2
(en)
*
|
2013-03-08 |
2016-11-29 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PT3083556T
(pt)
|
2013-12-19 |
2020-03-05 |
Novartis Ag |
Lípidos e composições lipídicas para a entrega de agentes ativos
|
|
DK3350157T3
(da)
|
2015-09-17 |
2022-02-14 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
|
|
PT3368507T
(pt)
|
2015-10-28 |
2023-02-07 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
|
CA3043033A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Improved ice-based lipid nanoparticle formulation for delivery of mrna
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
AU2019384557B2
(en)
|
2018-11-21 |
2025-07-17 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
|
|
WO2021038508A1
(en)
|
2019-08-30 |
2021-03-04 |
Glaxosmithkline Biologicals Sa |
Jet mixing lipid nanoparticle manufacturing process
|
|
DE102019214469A1
(de)
|
2019-09-23 |
2021-03-25 |
Henkel Ag & Co. Kgaa |
Kit und Verfahren zum Färben von keratinischem Material mit Aminosilikon und farbgebender Verbindung
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|